Israeli medical machine firm SoniVie, which is creating a proprietary resolution to deal with hypertension, introduced as we speak the completion of a $60 million collection C financing spherical led by Andera Companions, with participation from Supernova Make investments and Omega Funds. Earlier SoniVie investor TechWald additionally participated.
SoniVie has additionally appointed two main medtech specialists to its board of administrators, Raymond W. Cohen and Zeev Zehavi, as unbiased administrators.
SoniVie has developed an ultrasound-based denervation know-how with utility in a number of therapeutic areas. TIVUS (Therapeutic Intra-Vascular Ultrasound System) employs high-frequency non-focused ultrasound power to ablate nerves within the renal artery to lower blood stress. This minimally invasive investigational process can be utilized to deal with sufferers affected by hypertension, which impacts tens of millions of individuals worldwide and considerably will increase their danger of coronary heart assault, stroke and kidney failure.
TIVUS has energetic improvement applications in three therapeutic areas: pulmonary artery denervation for pulmonary hypertension, renal artery denervation for resistant hypertension, and lung denervation for persistent obstructive pulmonary illness with persistent bronchitis.
SoniVie will use the brand new financing to achieve medical and regulatory milestones and to assist its TIVUS renal artery denervation program.
SoniVie CEO Tomaso Zambelli mentioned, “We’re more than happy that this financing spherical concluded with such a powerful success. The brand new traders and the Board of Administrators carry vital expertise to the Firm within the area of Renal Denervation for Hypertension.”
Revealed by Globes, Israel enterprise information – en.globes.co.il – on January 9, 2023.
© Copyright of Globes Writer Itonut (1983) Ltd., 2023.